Yana Rage Hadarin Fasalar Zuciya da 38%! Tirzepatide Yana Sake fasalin Yanayin Jiyya na Zuciya

Tirzepatide, wani labari mai agonist dual receptor agonist (GLP-1/GIP), ya sami kulawa sosai a cikin 'yan shekarun nan saboda rawar da yake takawa wajen maganin ciwon sukari. Duk da haka, yuwuwar sa a cikin cututtukan zuciya da jijiyoyin jini yana fitowa a hankali. Nazarin kwanan nan ya nuna cewa tirzepatide yana nuna tasiri mai ban mamaki a cikin marasa lafiya tare da gazawar zuciya tare da ɓangarorin da aka kiyaye su (HFpEF) tare da kiba da cututtukan koda na yau da kullun (CKD). Gwajin asibiti na SUMMIT ya nuna cewa marasa lafiya da ke karɓar tirzepatide sun sami raguwar 38% a cikin haɗarin mutuwar cututtukan zuciya ko gazawar zuciya a cikin makonni 52, yayin da alamun aikin koda kamar eGFR ya inganta sosai. Wannan binciken yana ba da sabuwar hanyar warkewa ga marasa lafiya tare da rikice-rikice masu rikitarwa.

A cikin filin na zuciya da jijiyoyin jini, tsarin aikin tirzepatide ya wuce tsarin tsarin rayuwa. Ta hanyar kunna duka GLP-1 da masu karɓa na GIP, yana rage yawan adipocytes, ta haka ne ke rage karfin injin kitse a cikin zuciya da haɓaka makamashin zuciya na zuciya da ƙarfin anti-ischemic. Ga marasa lafiya na HFpEF, kiba da kumburi na yau da kullun sune masu ba da gudummawa mai mahimmanci, kuma tirzepatide's dual-receptor activation da kyau yana hana sakin cytokine mai kumburi kuma yana rage fibrosis na myocardial, ta haka yana jinkirta tabarbarewar aikin zuciya. Bugu da ƙari, yana haɓaka ƙimar rayuwar da aka ba da rahoton haƙuri (kamar KCCQ-CSS) da ƙarfin motsa jiki.

Tirzepatide kuma yana nuna sakamako mai ban sha'awa a cikin kariyar koda. CKD sau da yawa yana tare da rikice-rikice na rayuwa da ƙananan kumburi. Magungunan yana aiki ta hanyoyi guda biyu: haɓaka hemodynamics na glomerular don rage proteinuria, da kuma hana kai tsaye kan aiwatar da fibrosis na koda. A cikin gwajin SUMMIT, tirzepatide ya haɓaka matakan eGFR sosai dangane da cystatin C da rage albuminuria ba tare da la'akari da ko marasa lafiya suna da CKD ba, yana nuna cikakkiyar kariya ta koda. Wannan binciken ya buɗe sabuwar hanya don magance ciwon sukari nephropathy da sauran cututtukan koda.

Ko da abin lura shine keɓaɓɓen ƙimar tirzepatide a cikin marasa lafiya tare da “triad” na kiba, HFpEF, da CKD-ƙungiyar da ke da ƙarancin tsinkaye. Tirzepatide yana inganta tsarin jiki (rage tarin kitse da haɓaka haɓakar ƙwayar tsoka) kuma yana daidaita hanyoyin kumburi, ta haka yana ba da kariyar haɗin gwiwa a tsakanin gabobin da yawa. Kamar yadda alamun tirzepatide ke ci gaba da fadadawa, yana shirye ya zama maganin ginshiƙi a cikin kula da cututtuka na rayuwa tare da cututtuka.